We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
151
Spyre Therapeutics
SYRE
$8.25B
– –
-233
Closed -$43K
TXMD icon
152
TherapeuticsMD
TXMD
$26.4M
– –
-22
Closed -$8K
WST icon
153
West Pharmaceutical
WST
$24.6B
– –
-138
Closed -$11K
NVRO
154
DELISTED
NEVRO CORP.
NVRO
– –
-217,292
Closed -$20.4M
RCM
155
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-17,976
Closed -$56K
TCON
156
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
0
– –
MDRX
157
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-42,955
Closed -$545K
NXGN
158
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-33,875
Closed -$516K
CYTO
159
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-5
Closed -$368K
ZYNE
160
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-251,328
Closed -$5M
ISEE
161
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,600
Closed -$5K
BLCM
162
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-8,620
Closed -$1.06M
AGRX
163
DELISTED
Agile Therapeutics
AGRX
– –
0
– –
ABMD
164
DELISTED
Abiomed Inc
ABMD
– –
-85,000
Closed -$10.6M
CLVS
165
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-157,754
Closed -$10M
AERI
166
DELISTED
Aerie Pharmaceuticals
AERI
– –
-50,000
Closed -$2.27M
EPZM
167
DELISTED
Epizyme, Inc
EPZM
– –
-1,165
Closed -$20K
PRAH
168
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-8,308
Closed -$542K
FPRX
169
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-127
Closed -$5K
HMSY
170
DELISTED
HMS Holdings Corp.
HMSY
– –
-26,553
Closed -$540K
AMAG
171
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-560,000
Closed -$12.6M
IMMU
172
DELISTED
Immunomedics Inc
IMMU
– –
-300,060
Closed -$1.94M
AKRX
173
DELISTED
Akorn Inc
AKRX
– –
-40,000
Closed -$963K
QHC
174
DELISTED
Quorum Health Corporation
QHC
– –
-50,604
Closed -$275K
RARX
175
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-100,000
Closed -$2.13M
4 5 6
7
8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.